No-Aspirin (NCX 4016) [7]

Gastroenterology

Volumn 125, Issue 6, 2003, Pages 1918-1919

  Mann, Nirmal S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0345490978     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.05.015     Document Type: Letter

References (6)

1. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003;124:600-607.
2. Wallace JL, Ignaro Li, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 2002;1:375-382.
3. Peura DA. Mandate to modify a medicinal mantra: may be not yet. Gastroenterology 2003;124:842-843.
4. Spirili C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, LaRusso NF, Sonzogni A, Okolicsanyi L, Strazzabosco M. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and CAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124:737-753.
5. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000;119:512-520.
6. Trauner M. When bile ducts say NO: the good, the bad, and the ugly. Gastroenterology 2003;124:847-851.